Le Lézard
Classified in: Health, Business
Subjects: SVY, WOM

New Maven Report: Why Investing in Return-to-Work Benefits is a Billion Dollar Opportunity for Companies


NEW YORK, Oct. 13, 2017 /PRNewswire/ -- In the United States, more than 75% of expecting mothers say they are excited to go back to work after giving birth. But in the end, 43% of them end up leaving their jobs. One aspect that is often underexplored is the direct role healthcare plays in this dynamic.

With approximately 1 out of 2 babies born on corporate health plans, companies, without many federal policies in place around parental leave or postpartum care, are inadvertently in the driver's seat in defining maternity care in America.

"Returning to work after maternity leave is a crucial part of women's health that folks are just beginning to grapple with in a serious way," says Kate Ryder, Maven's Founder and CEO. "Having served companies for two years with our return-to-work program, Maven is committed to continuing to deliver best-in-class care in this area?and drive this important conversation forward in a meaningful way."

Report highlights:                                          

Read the full report here: www.mavenclinic.com/back-to-work

About Maven:  
Maven is the digital clinic for women, giving on-demand access to its proprietary network of best-in-class women's health practitioners via video or private text. Maven operates both an on-demand consumer marketplace in addition to its family benefits platform, Maven Maternity, which offers clinical programs around fertility, prenatal, postpartum, and return-to-work. Maven has helped over 100,000 women get care, and works with employers with as few as 200 and as many as 200,000 employees. Maven was founded in 2014 by Katherine Ryder and has raised more than $15m.

 

SOURCE Maven


These press releases may also interest you

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...



News published on and distributed by: